Purpose: Irreversible EGFR-tyrosine kinase inhibitors (TKI) are thought to be one strategy to
overcome EGFR-TKI resistance induced by T790M gatekeeper mutations in non–small cell …

Gefitinib is a first-line therapy in the EGFR-mutated nonsmall cell lung cancer (NSCLC).
However, the development of drug resistance is almost unavoidable, thus leading to an …

Osimertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), is commonly used to
treat EGFR-mutant non-small-cell lung cancer (NSCLC). However, acquired resistance to …

The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib has
significantly prolonged progression-free survival (PFS) in patients with EGFR-mutant lung …

Introduction Osimertinib is the current recommended treatment for EGFR T790M–positive
NSCLC after EGFR tyrosine kinase inhibitor therapy. However, resistance to osimertinib …

The clinical success of EGFR inhibitors in patients with lung cancer is limited by the
inevitable development of treatment resistance. Here, we show that inhibition of SREBP …

Introduction Oral administration of ritonavir-boosted nirmatrelvir (Paxlovid) was found to be
promising in the treatment of coronavirus disease 2019. The active antiviral component …

Background: Patients with non-small cell lung cancer (NSCLC) initially responding to
tyrosine kinase inhibitors (TKIs) eventually develop resistance due to accumulating …

Tyrosine kinase inhibitors (TKIs) have been widely used for the clinical treatment of patients
with non-small cell lung cancer (NSCLC) harboring mutations in the EGFR. Unfortunately …

Exploring resistance mechanisms in patients with EGFR-mutant non-small-cell lung cancer
(NSCLC) upon disease progression on EGFR tyrosine kinase inhibitors (TKIs) has been an …